Triethylamine → (R)-[4-amino-1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)piperidine]

HRID 1814806ノート

反応式

HRID 1814806 の反応式
C(OC([NH:8][CH:9]1[CH2:14][CH2:13][NH:12][CH2:11][CH2:10]1)=O)(C)(C)C.C(N(CC)CC)C.[F:22][C:23]([F:35])([F:34])[C@@:24]([O:29][Si](C)(C)C)([CH3:28])[C:25](Cl)=[O:26]>C(Cl)Cl>[NH2:8][CH:9]1[CH2:10][CH2:11][N:12]([C:25](=[O:26])[C@:24]([OH:29])([CH3:28])[C:23]([F:35])([F:34])[F:22])[CH2:13][CH2:14]1

参加物

5

実験手順

To a solution of 4-t-butyloxycarbonylaminopiperidine (Method C, 8.0 g, 40.0 mmol) and triethylamine (8.5 ml), 60 mmol) in DCM (200 ml) was added a solution of (S)-3,3,3-trifluoro-2-trimethylsilyloxy-2-methylpropanoyl chloride (J. Med. Chem., 1999, 42, 2741-2746) (10.0 g, 41.3 mmol) in DCM (5 ml). The resultant mixture was stirred at ambient temperature overnight, the DCM evaporated, the residue taken up in EtOAc (150 ml), washed with saturated citric acid solution, saturated sodium hydrogen carbonate solution and brine, dried and evaporated. The residue was dissolved in methanol (25 ml), treated with saturated hydrogen chloride in methanol (100 ml), stirred at ambient temperature overnight and evaporated to dryness. The residue was recrystallized from methanol/EtOAc to give the title compound as the hydrochloride salt (7.5 g, 27.2 mmol). Mp: 245-246° C.; NMR: 1.45 (m, 2H), 1.5 (s, 3H), 1.95 (m, 2H), 3.25 (m, 1H), 4.4 (m, 2H), 4.65 (m, 2H), 7.15 (s, 1H), 8.2 (s, 3H); m/z (+ve ESP) 241 (M+H)+.

後処理

  1. customthe DCM evaporated
  2. washwashed with saturated citric acid solution, saturated sodium hydrogen carbonate solution and brine
  3. customdried
  4. customevaporated
  5. dissolutionThe residue was dissolved in methanol (25 ml)
  6. additiontreated with saturated hydrogen chloride in methanol (100 ml)
  7. customevaporated to dryness
  8. customThe residue was recrystallized from methanol/EtOAc

出典と根拠

ORDレコード
ord-44f5c5c8f60140e09160b961ec0b1064
出典データセット
uspto-grants-2005_04
特許番号
US06878712B1

反応ノート

読み込み中…